1-12 of 12
Robert F. Cornell
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Progression-Free Survival and Treatment Patterns for t(11;14) Positive Patients with Multiple Myeloma with at Least 2 Prior Lines of Treatment

Allicia Girvan, Daniel Martins, Junhua Yu, Sophia Ng, Rajesh Kamalakar, Faiza Zafar, Seema Tulsian, Robert F. Cornell, Mohamed Samir
Journal: Blood
Blood (2023) 142 (Supplement 1): 6667.
https://doi.org/10.1182/blood-2023-173446
Published: 2023
Journal Articles

Treatment Patterns and Outcomes in Patients with Relapsed/Refractory Multiple Myeloma Receiving ≥3 Lines of Therapy: A Real-World Evaluation in the United States

Allicia Girvan, Junhua Yu, Rajesh Kamalakar, Elizabeth S. Mearns, Michael Nixon, Robert F. Cornell
Journal: Blood
Blood (2022) 140 (Supplement 1): 5288–5290.
https://doi.org/10.1182/blood-2022-156225
Published: 2022
Journal Articles

Biologic Basis of the Impact of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma Treated with Quadruplet Therapy

Susan Bal, Saurabh Chhabra, Natalie S. Callander, Eva Medvedova, Bhagirathbhai Dholaria, Rebecca W. Silbermann, Kelly N. Godby, Binod Dhakal, Smith Giri, Anita d'Souza, Timothy M. Schmidt, Aric C. Hall, Pamela Hardwick, Robert F. Cornell, Parameswaran Hari, Luciano J. Costa
Journal: Blood
Blood (2021) 138 (Supplement 1): 483.
https://doi.org/10.1182/blood-2021-145533
Published: 2021
Journal Articles

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd), Autologous Transplantation and MRD Response-Adapted Consolidation and Treatment Cessation. Final Primary Endpoint Analysis of the Master Trial

Luciano J. Costa, Saurabh Chhabra, Natalie S. Callander, Eva Medvedova, Bhagirathbhai Dholaria, Rebecca W. Silbermann, Kelly N. Godby, Binod Dhakal, Susan Bal, Smith Giri, Anita d'Souza, Timothy M. Schmidt, Aric C. Hall, Pamela Hardwick, Robert F. Cornell, Parameswaran Hari
Journal: Blood
Blood (2021) 138 (Supplement 1): 481.
https://doi.org/10.1182/blood-2021-145494
Published: 2021
Journal Articles

A Phase 1 First-in-Human Study of the Anti-CD38 Dimeric Fusion Protein TAK-169 for the Treatment of Patients (pts) with Relapsed or Refractory Multiple Myeloma (RRMM) Who Are Proteasome Inhibitor (PI)- and Immunomodulatory Drug (IMiD)-Refractory, Including Pts Relapsed/Refractory (R/R) or Naïve to Daratumumab (dara)

Shaji K. Kumar, MD, Robert F. Cornell, MD MS, Ola Landgren, MD PhD, Sikander Ailawadhi, MD, Jack P Higgins, PhD, Erin K Willert, Roger Waltzman, MD MBA, Jianchang Lin, PhD, Yuhong Zhang, Anya R Lublinsky, Ajeeta B Dash, PhD, Michael Hanley, Divya Manoharan, Morgan Leichter, Sean Ottinger, Richard J Labotka, John Newcomb, Alexander Vorog, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1867.
https://doi.org/10.1182/blood-2019-125629
Published: 2019
Journal Articles

Safety, Clinical Activity, Pharmacokinetics, and Pharmacodynamics from a Phase I Study of PF-06863135, a B-Cell Maturation Antigen (BCMA)-CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Noopur S. Raje, MD, Andrzej Jakubowiak, MD PhD, Cristina Gasparetto, MD, Robert F. Cornell, MD MS, Heike I. Krupka, PhD PMP, Daniel Navarro, MD MSc, Alison J. Forgie, DPhil, Chandrasekhar Udata, PhD, Cynthia Basu, PhD, Jeffrey Chou, MD PhD, Abraham Leung, MD, Alexander M. Lesokhin, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1869.
https://doi.org/10.1182/blood-2019-121805
Published: 2019
Journal Articles

Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM)

Luciano J. Costa, MD PhD, Saurabh Chhabra, MD, Kelly N. Godby, MD, Eva Medvedova, MD, Robert F. Cornell, MD MS, Aric C. Hall, MD, Rebecca W. Silbermann, MD, Racquel Innis-Shelton, MD, Binod Dhakal, MBBS, Diego DeIdiaquez, MD, Pamela Hardwick, RN, Yelak Biru, James L. Omel, MD, Parameswaran Hari, MBBS, MD, Natalie Scott Callander, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 860.
https://doi.org/10.1182/blood-2019-123170
Published: 2019
Journal Articles

Overall Survival of Triple Class Refractory, Penta-Exposed Multiple Myeloma (MM) Patients Treated with Selinexor Plus Dexamethasone or Conventional Care: A Combined Analysis of the STORM and Mammoth Studies

Luciano J. Costa, MD PhD, Parameswaran Hari, MBBS, MD, Shaji K. Kumar, MD, Shijie Tang, Ujjawal H Gandhi, PhDMBBS, Jatin J. Shah, MD, Sundar Jagannath, MD, Ajai Chari, MD, Arjun Lakshman, MBBS, Sharon Shacham, PhD MBA, Xiwen Ma, David S. Siegel, Noa Biran, MD, Sagar Lonial, Paul G. Richardson, MD, Michael G. Kauffman, MD PhD, Ehsan Malek, MD, Kelly N. Godby, MD, Mark A. Fiala, BS, Saurabh Chhabra, MD, Saad Z. Usmani, MD, Natalie Scott Callander, MD, Yubin Kang, MD, Amarendra K. Neppalli, MD, Elvira Umyarova, MD, Robert F. Cornell, MD MS
Journal: Blood
Blood (2019) 134 (Supplement_1): 3125.
https://doi.org/10.1182/blood-2019-124991
Published: 2019
Journal Articles

Ibrutinib Therapy in Rituximab-Refractory Patients with Waldenström's Macroglobulinemia: Initial Results from an International, Multicenter, Open-Label Phase 3 Substudy (iNNOVATE TM )

Meletios A. Dimopoulos, MD, Judith Trotman, FRACP, Alessandra Tedeschi, MD, Jeffrey V. Matous, MD, David Macdonald, MD MSc, FRCPC, Constantine Tam, MBBS, MD, Oliver Tournilhac, MD, Shuo Ma, MD PhD, Albert Oriol, MDPhD, Leonard T. Heffner, MD, Chaim Shustik, MD, Ramón García-Sanz, MD PhD, Robert F. Cornell, Carlos Fernández de Larrea, MD PhD, Jorge J. Castillo, MD, Miquel Granell, MD, Marie-Christine Kyrtsonis, MD, Veronique Leblond, MD PhD, Argiris Symeonidis, MD PhD, Priyanka Singh, MS, Jianling Li, MS, Thorsten Graef, MD PhD, Elizabeth Bilotti, MSN, Steven Treon, MD PhD, Christian Buske, MD
Journal: Blood
Blood (2015) 126 (23): 2745.
https://doi.org/10.1182/blood.V126.23.2745.2745
Published: 2015
Journal Articles

Six-Minute Walk Test As a Measure of Functional Change after Chemotherapy in Cardiac AL Amyloidosis

Ilka Decker, MD MS, Oluchi C. Ukaegbu, MD, Stacey A. Goodman, MD MS, Daniel J. Lenihan, MD, Rebecca R Hung, MD, Adetola A. Kassim, MD MS, Shelton L. Harrell, MSN, ACNP-BC, Kevin McDonagh, MD, Sharon E. Phillips, MSPH, Kyle T Rawling, Samuel M Rubinstein, MD, Tarsheen K. Sethi, MD MS, Robert F Cornell, MD MS
Journal: Blood
Blood (2015) 126 (23): 1841.
https://doi.org/10.1182/blood.V126.23.1841.1841
Published: 2015
Journal Articles

Risk Factors for Cardiac Toxicities Associated with Proteasome Inhibitor Chemotherapy during Treatment of Multiple Myeloma

John H. Chen, Daniel J. Lenihan, MD, Sharon E. Phillips, MSPH, Madan H. Jagasia, Stacey A. Goodman, MD MS, Adetola A. Kassim, MD MS, Shelton L. Lacy, Kevin T. McDonagh, Javid J. Moslehi, MD, Tarsheen K. Sethi, MD MS, David A. Slosky, Oluchi C. Ukaegbu, MD, Robert F. Cornell
Journal: Blood
Blood (2015) 126 (23): 5363.
https://doi.org/10.1182/blood.V126.23.5363.5363
Published: 2015
Journal Articles

In the Era of Bortezomib-Based Chemotherapy the Presence of Minimal Residual Disease Predicts Progression Free Survival after Autologous Hematopoietic Cell Transplant

Robert F Cornell, MD MS, Jade E Jones, Claudio A. Mosse, Heidi Chen, Laura Dugger, Salil Goorha, Wichai Chinratanalab, Brian Engelhardt, Stacey A. Goodman, MD MS, John P Greer, Shelton Lacy, Adetola A. Kassim, MD MS, Kevin McDonagh, Bipin N. Savani, MD, Salyka Sengsayadeth, Madan Jagasia
Journal: Blood
Blood (2015) 126 (23): 5493.
https://doi.org/10.1182/blood.V126.23.5493.5493
Published: 2015